Zelira Therapeutics (AU:ZLD)
ASX:ZLD
Want to see AU:ZLD full AI Analyst Report?
ZLD Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume190.00
Average Volume (3M)1.92K
Market Cap
AU$5.95M
Enterprise ValueAU$8.08M
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Monetization StrategyZelira’s explicit dual monetization model — direct commercialization plus licensing and co-development — provides structural optionality. Over months this supports multiple revenue levers, lets the firm pursue higher-margin B2B deals while retail builds, and reduces dependence on a single sales channel.
Proprietary Cannabinoid FormulationsA product set centered on proprietary cannabinoid formulations creates a durable competitive asset if clinical or formulation differentiation persists. For 2–6 months this supports licensing appeal, niche market positioning (sleep/wellness), and potential higher margins vs. commodity suppliers.
Lean Operating StructureAn eight-person headcount indicates a lean fixed-cost base that can materially reduce cash burn relative to larger peers. Structurally, a small team helps extend runway, focus on partnerships/licensing, and preserve capital while pursuing product commercialization or B2B deals.
Bears Say
Severe Revenue CollapseA near-total revenue decline erodes the company’s core commercialization proof points and undermines scale economics. Over the next several months this diminishes bargaining power with partners, restricts reinvestment in R&D or marketing, and makes operational recovery materially harder.
Negative Shareholders' EquityNegative equity signals liabilities exceed assets and implies balance-sheet fragility. This structural weakness limits access to traditional debt, increases likelihood of dilutive equity raises or onerous financing, and can impede long-term partnering or large commercial agreements.
Persistently Negative Cash FlowOngoing negative operating and free cash flows constrain the company’s ability to fund commercialization, clinical work, or scale manufacturing internally. Over a multi-month horizon this raises reliance on external funding or partner milestones, elevating execution and dilution risk.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$5.95M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 86 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions, including chronic pain, sleep disorders, and other serious ailments. The company leverages its proprietary formulations and clinical research to create products that are designed to improve patient outcomes and quality of life.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―